Sickle-Cell Anemia Therapeutics Market in the US 2018-2022
About this market
Sickle- cell anemia treatment is associated with high cost medications in the US. To reduce the treatment burden on the patients, several companies and government organizations are offering reimbursement for the treatment. Several stakeholders are offering partnerships to work with state and local policyholders and the payer group to ensure the payment and reimbursement are in place so that the providers can be supported to advance access to quality care. Technavio’s analysts have predicted that the sickle-cell anemia therapeutics market in the US will register a CAGR of over 15% by 2022.
Market Overview
Recent product approvals for sickle- cell anemia
Due to fewer product availability in the US for the treatment of sickle- cell anemia, hence these recently approved products drive the market over the forecast period.
Limited number of approved drugs
The availability of very limited approved therapies for the treatment of sickle- cell anemia id the US is expected to hamper the growth of the market during our forecast period.
For the detailed list of factors that will drive and challenge the growth of the sickle-cell anemia therapeutics market in the US during the 2018-2022, view our report.
Competitive Landscape
The sickle-cell anemia therapeutics market in the US is highly concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
PRESS RELEASE
Technavio Announces the Publication of its Research Report – Sickle-Cell Anemia Therapeutics Market in the US 2018-2022
Technavio recognizes the following companies as the key players in the sickle-cell anemia therapeutics market in the US: Bristol-Myers Squibb, Emmaus Medical, Medunik USA.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the research on the development of gene therapy to treat sickle- cell anemia is a new approach.
According to the report, one of the major drivers for this market is the awareness’s programs are expected to increase the focus on disease diagnosis and treatment options. Therefore, leading to the growth of the sickle- cell anemia therapeutics market in the US over the forecast period.
Further, the report states that one of the major factors hindering the growth of this market is the stringent government regulations for marketing approval are expected to restrict the market growth during the forecast period.
Companies Mentioned
Bristol-Myers Squibb
Emmaus Medical
and Medunik USA
- Executive summary
- Scope of the report
- Research methodology
- Market landscape
- Market ecosystem
- Table Parent market
- Table Global hematology market
- Market characteristics
- Table Market characteristics
- Market segmentation analysis
- Table Market segments
- Market ecosystem
- Market sizing
- Market definition
- Table Market definition - Inclusions and exclusions checklist
- Market sizing 2017
- Table Market size 2017
- Table Validation techniques: Market sizing Applied
- Market size and forecast 2017-2022
- Table Market size and forecast 2017-2022 ($ mn)
- Table Year-over-year growth 2018-2022 (%)
- Market definition
- Five forces analysis
- Table Five forces analysis 2017
- Table Five forces analysis 2022
- Bargaining power of buyers
- Table Bargaining power of buyers
- Bargaining power of suppliers
- Table Bargaining power of suppliers
- Threat of new entrants
- Table Threat of new entrants
- Threat of substitutes
- Table Threat of substitutes
- Threat of rivalry
- Table Threat of rivalry
- Market condition
- Table Market condition - Five forces 2017
- Market segmentation by therapy
- Segmentation by therapy
- Table Therapy - Market share 2017-2022 (%)
- Comparison by therapy
- Table Comparison by therapy
- Hydroxyurea - Market size and forecast 2017- 2022
- Table Hydroxyurea - Market size and forecast 2017-2022 ($ mn)
- Table Hydroxyurea - Year-over-year growth 2018-2022 (%)
- L-glutamine therapy- Market size and forecast 2017-2022
- Table L-glutamine therapy - Market size and forecast 2017-2022 ($ mn)
- Table L-glutamine therapy - Year-over-year growth 2018-2022 (%)
- Market opportunity by therapy
- Table Market opportunity by therapy
- Segmentation by therapy
- Customer landscape
- Table Customer landscape
- Decision framework
- Drivers and challenges
- Market drivers
- Market challenges
- Market trends
- Introduction of gene therapy
- Strategic alliances
- Orphan drug designations for sickle-cell anemia
- Vendor landscape
- Overview
- Table Vendor landscape
- Landscape disruption
- Table Landscape disruption
- Overview
- Vendor analysis
- Vendors covered
- Table Vendors covered
- Vendor classification
- Table Vendor classification
- Market positioning of vendors
- Table Market positioning of vendors
- Bristol-Myers Squibb
- Table Bristol-Myers Squibb – Overview
- Table Bristol-Myers Squibb - Business segments
- Table Bristol-Myers Squibb - Organizational developments
- Table Bristol-Myers Squibb - Geographic focus
- Table Bristol-Myers Squibb - Segment focus
- Table Bristol-Myers Squibb - Key offerings
- Table Bristol-Myers Squibb - Key customers
- Emmaus Medical
- Table Emmaus Medical – Overview
- Table Emmaus Medical - Organizational developments
- Table Emmaus Medical - Geographic focus
- Table Emmaus Medical - Key offerings
- Table Emmaus Medical - Key customers
- Medunik USA
- Table Medunik USA – Overview
- Table Medunik USA - Organizational developments
- Table Medunik USA - Key offerings
- Table Medunik USA - Key customers
- Vendors covered
- Appendix
- List of abbreviations
- Explore Technavio
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook